In light of this, this study aimed to assess the adherence of physicians to ADA recommendations in the prescription of SGLT2 inhibitors and GLP1-RAs - medications that offer proven cardiovascular benefits - to patients with type 2 diabetes and established ASCVD or those with indications of high ASCVD risk, as well as in the prescription of SGLT2 inhibitors to heart failure patients. This evidence concerns the gene SLC5A2 and heart failure.